News | August 06, 2009

IG-IMRT Feasible for Patients with Biliary Adenocarcinomas

August 6, 2009 - In comparison to a cohort of patients treated by conventional radiation techniques, image-guided intensity-modulated RT (IG-IMRT) was feasible for biliary tract tumors, and the median survival was nearly double that in the group treated with conventional RT.

This study is the first clinical outcomes of biliary tract cancers treated with IG-IMRT, warranting further investigation in prospective clinical trials.

Biliary tract lesions are comparatively rare neoplasms, with ambiguous indications for radiotherapy. The purpose of the study was to report the clinical results of a single-institution biliary tract series treated with modern radiotherapeutic techniques, and detail results using both conventional and image-guided intensity-modulated radiation therapy (IG-IMRT).

In the stidy, 24 patients with primary adenocarcinoma of the biliary tract (gallbladder and extrahepatic bile ducts) were treated by IG-IMRT from 2001 to 2005. To compare outcomes, data from a sequential series of 24 patients treated between 1995 and 2005 with conventional radiotherapy (CRT) techniques were collected as a comparator set. Demographic and treatment parameters were collected. Endpoints analyzed included treatment-related acute toxicity and survival.

The results showed a median estimated survival for all patients completing treatment was 13.9 months. A statistically significant higher mean dose was given to patients receiving IG-IMRT compared to CRT, 59 vs. 48 Gy. IGIMRT and CRT cohorts had a median survival of 17.6 and 9.0 months, respectively. Surgical resection was associated with improved survival. Two patients (4 percent) experienced an RTOG acute toxicity score > 2. The most commonly reported GI toxicities (PRTOG Grade 2) were nausea or diarrhea requiring oral medication, experienced by 46 percent of patients.

Source: Radiother Oncol. 2009 Aug 1;92(2):249-254, CD Fuller, ND Dang, SJ Wang, P Desai, M Choi, CR Thomas, M Fuss.

For more information: www.oncologystat.com

Related Content

News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
News | Image Guided Radiation Therapy (IGRT) | July 13, 2017
Elekta and Sunnybrook Health Sciences Centre have initiated installation of Elekta’s MR-linac, an investigational...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
Henry Ford Cancer Institute First in World to Install Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 19, 2017
The Henry Ford Cancer Institute is the first in Michigan – and first in the world – to offer patients advanced...
News | Image Guided Radiation Therapy (IGRT) | May 24, 2017
The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as part of a clinical...
Mevion and medPhoton Bring Advanced Cone Beam CT Imaging to Proton Therapy
News | Proton Therapy | May 04, 2017
Mevion Medical Systems announced a strategic agreement with medPhoton GmbH to integrate ImagingRing, an innovative cone...
ViewRay, MRIdian Linac system, FDA 510k approval, MRI-guided radiation therapy
Technology | Image Guided Radiation Therapy (IGRT) | February 27, 2017
February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S.
Overlay Init